Study of PlasmaCap IG in Adults and Children With PIDD



Status:Recruiting
Conditions:HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:2 - 70
Updated:4/4/2019
Start Date:September 5, 2017
End Date:May 2020
Contact:Jacinthe Guindon
Email:jguindon@therapurebio.com
Phone:1-289-327-2253

Use our guide to learn which trials are right for you!

A Prospective, Open-Label, Multicenter Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of Therapure PlasmaCap IG in Adults and Children With Primary Immune Deficiency Diseases

The purpose of this study is to investigate the efficacy, safety, tolerability, and
pharmacokinetic profile of the investigational medicinal product (IMP) and to determine, on
the basis of historical control data, how it compares with other 10% intravenous
immunoglobulin (IGIV) products currently licensed in North America for the treatment of
subjects with primary immune deficiency diseases (PIDD).


Inclusion Criteria:

- Subject has a confirmed clinical diagnosis of a PIDD, which requires treatment with
IGIV:

- Subject/guardian has provided written informed consent (and assent, as applicable).

- Subject is between the ages of 2 and 70 years.

- Subject has received regular IGIV therapy at 21- or 28-day (±4 days) intervals for at
least three consecutive months at a dose between 300-900 mg/kg/month prior to
Screening or;

- Subject has received commercial SCIG at a dose of 300-900 mg/kg/month on any dosing
schedule for at least 12 consecutive weeks prior to Screening. Subjects on SCIG must
have received and tolerated IGIV treatment prior to SCIG treatment.

- Subject has a documented trough of ≥500 mg/dL in the 6 months prior to screening.

- Females of childbearing potential must be willing to use an effective form of birth
control (eg, oral contraceptives) for the duration of the study, per IRB/REB
guidelines.

- Subject agrees to comply with the requirements of the protocol.

Exclusion Criteria:

- Subject has secondary immunodeficiency.

- Subject has history of thrombotic events, such as deep vein thrombosis, myocardial
infarction, cerebrovascular accident, pulmonary embolism, etc within the year prior to
screening.

- Subject has had an immune globulin associated arterial or venous
thrombotic/thromboembolic event (TEE) within 7 days of infusion or a TEE that is not
associated with an immune globulin within one year of screening.

- Subject has received blood products (except for IGIV, SCIG, or albumin) within 6
months of screening.

- Subject has anemia (≤8.5 g/dL).

- Subject has levels of alanine aminotransferase (ALT) or aspartate aminotransferase
(AST) >3.0 times the upper limit of normal (ULN).

- Subject has severe neutropenia (≤1000 neutrophils per mm3).

- Subject is receiving other immunosuppressive or immunomodulatory drugs or
chemotherapy.

- Subject is taking or has taken within the four weeks prior to screening prednisone at
≥0.15 mg/kg/day for more than 10 days.

- Subject has ever had a severe anaphylactic reaction to a blood or IgG product.

- Subject has lymphoid malignancy, leukemia, or any other history of malignancy within
the past five years, except squamous cell or basal cell carcinoma of the skin (not
melanoma).

- Subject has hypoalbuminemia, protein-losing enteropathy, or proteinuria greater than
300 mg/24 hours except for subjects with documented orthostatic proteinuria.

- Subject has immunoglobulin A (IgA) deficiency with known antibodies to IgA.

- Female who is pregnant, breastfeeding, or planning a pregnancy during the course of
the study (women who become pregnant during the study will be withdrawn from the
study).

- Any condition that is likely to interfere with evaluation of IMP or satisfactory
conduct of the trial in the PI's opinion.

- Subjects who may not be compliant or have a history of non-compliance in the opinion
of the PI.
We found this trial at
14
sites
?
mi
from
Dallas, TX
Click here to add this to my saved trials
4202 E Fowler Ave
Tampa, Florida 33620
(813) 974-2011
University of South Florida The University of South Florida is a high-impact, global research university...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
6801 South Yosemite Street
Centennial, Colorado 80112
?
mi
from
Centennial, CO
Click here to add this to my saved trials
Charlotte, North Carolina 28204
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Chevy Chase, Maryland 20815
?
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Columbus, Ohio 43235
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Dallas, Texas 75231
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Irving, Texas 75063
?
mi
from
Irving, TX
Click here to add this to my saved trials
Little Silver, New Jersey 07739
?
mi
from
Little Silver, NJ
Click here to add this to my saved trials
Los Angeles, California 90095
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
3175 Chemin de la Côte-Sainte-Catherine
Montreal, Quebec H3T 1C5
?
mi
from
Montreal,
Click here to add this to my saved trials
Richland, Washington 99352
?
mi
from
Richland, WA
Click here to add this to my saved trials
840 U.S. 1
West Palm Beach, Florida 33408
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials